Alzheimer's Disease: Mechanisms and Therapeutic Advances
- 1Institute of Basic Theory For Chinese Medicine China Academy of Chinese Medical Sciences Beijing China
Abstract
Alzheimer's disease (AD) is a devastating neurodegenerative condition accompanied by widespread central nervous system damage and complex networked pathogenesis spanning molecular, cellular, and systemic dimensions. Existing studies tend to focus on individual pathological cascades or monotherapeutic approaches, while overlooking the intrinsic crosstalk among protein pathology, neuroinflammation, metabolic dysfunction, and gut–brain axis imbalance, with insufficient systematic integration of nonpharmacological strategies and multifunctional nanoplatforms. Driven by intertwined molecular aberrations, glial dysregulation and systemic metabolic disorders, AD presents profound pathological complexity. Correspondingly, multitarget pharmacotherapy integrated with hierarchical nonpharmacological and nanotherapeutic interventions has achieved substantial progress, exerting synergistic effects on alleviating AD pathological cascades and optimizing overall therapeutic regimens. We comprehensively review current evidence to delineate the mechanistic landscape of AD and update therapeutic advances, including pharmacological agents, multimodal nonpharmacological interventions, and brain‐targeted nanosystems for blood–brain barrier penetration, protein modulation, microenvironment remodeling, and gene editing delivery. This study underscores major research limitations and translational obstacles in therapeutic efficacy, biosafety, and nanomedicine applications. This work emphasizes biomarker‐based early stratification and staged combined interventions, providing novel integrated insights into AD pathogenesis and prospective targeted therapeutic development.
Related
- Recent advances in Alzheimer’s disease: From molecular mechanisms to therapeutic strategies
- Natural Products for Pancreatitis: Recent Advances, Molecular Mechanisms and Therapeutic Prospects
- Immunoregulatory roles of the enteric nervous system in esophageal motility control: mechanisms, advances, and therapeutic potential
- The mitochondrial translocator protein (TSPO) in Alzheimer's disease: Therapeutic and immunomodulatory functions
- Kidney-Targeted Gene Transfer: Therapeutic Advances in Native Kidney Disease and Emerging Ex Vivo Allograft Engineering.
BibTeX
@article{fu2026alzheimers,
title = {{Alzheimer's Disease: Mechanisms and Therapeutic Advances}},
author = {Gaoshuang Fu and Mingmin Pan and Qingling Sun and Guangxin Yue and Tong Lei},
journal = {MedComm},
year = {2026},
month = nov,
doi = {10.1002/mco2.71093},
url = {https://doi.org/10.1002/mco2.71093},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Alzheimer's Disease: Mechanisms and Therapeutic Advances
AU - Gaoshuang Fu
AU - Mingmin Pan
AU - Qingling Sun
AU - Guangxin Yue
AU - Tong Lei
PY - 2026
DA - 2026/11/03
JO - MedComm
DO - 10.1002/mco2.71093
UR - https://doi.org/10.1002/mco2.71093
AB - Alzheimer's disease (AD) is a devastating neurodegenerative condition accompanied by widespread central nervous system damage and complex networked pathogenesis spanning molecular, cellular, and systemic dimensions. Existing studies tend to focus on individual pathological cascades or monotherapeutic approaches, while overlooking the intrinsic crosstalk among protein pathology, neuroinflammation, metabolic dysfunction, and gut–brain axis imbalance, with insufficient systematic integration of nonpharmacological strategies and multifunctional nanoplatforms. Driven by intertwined molecular aberrations, glial dysregulation and systemic metabolic disorders, AD presents profound pathological complexity. Correspondingly, multitarget pharmacotherapy integrated with hierarchical nonpharmacological and nanotherapeutic interventions has achieved substantial progress, exerting synergistic effects on alleviating AD pathological cascades and optimizing overall therapeutic regimens. We comprehensively review current evidence to delineate the mechanistic landscape of AD and update therapeutic advances, including pharmacological agents, multimodal nonpharmacological interventions, and brain‐targeted nanosystems for blood–brain barrier penetration, protein modulation, microenvironment remodeling, and gene editing delivery. This study underscores major research limitations and translational obstacles in therapeutic efficacy, biosafety, and nanomedicine applications. This work emphasizes biomarker‐based early stratification and staged combined interventions, providing novel integrated insights into AD pathogenesis and prospective targeted therapeutic development.
SN - 2688-2663
ER -